Chi Sheng Pharma & Biotech Co., Ltd Share Price

Equities

4111

TW0004111000

Pharmaceuticals

End-of-day quote Taipei Exchange 03:30:00 15/05/2024 am IST 5-day change 1st Jan Change
25.85 TWD -0.58% Intraday chart for Chi Sheng Pharma & Biotech Co., Ltd +0.19% -3.00%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 1.14B 35.64M 2.97B Sales 2023 1.06B 33.08M 2.76B Capitalization 1.52B 47.35M 3.95B
Net income 2022 154M 4.8M 400M Net income 2023 68M 2.12M 177M EV / Sales 2022 1.06 x
Net cash position 2022 328M 10.22M 852M Net cash position 2023 258M 8.05M 671M EV / Sales 2023 1.19 x
P/E ratio 2022
10.1 x
P/E ratio 2023
22.2 x
Employees -
Yield 2022
4.43%
Yield 2023
3.75%
Free-Float 76.71%
More Fundamentals * Assessed data
Dynamic Chart
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
More news
1 day-0.58%
1 week+0.19%
1 month-2.27%
3 months-0.39%
6 months-2.64%
Current year-3.00%
More quotes
1 week
25.80
Extreme 25.8
26.05
1 month
25.55
Extreme 25.55
26.60
Current year
25.30
Extreme 25.3
27.00
1 year
24.35
Extreme 24.35
30.50
3 years
21.60
Extreme 21.6
36.85
5 years
21.00
Extreme 21
36.85
10 years
15.58
Extreme 15.5769
40.48
More quotes
Managers TitleAgeSince
Chief Executive Officer - 18/03/18
Director of Finance/CFO - -
Members of the board TitleAgeSince
Director/Board Member - 18/03/18
Director/Board Member - 13/12/13
Director/Board Member - 13/12/13
More insiders
Date Price Change Volume
15/24/15 25.85 -0.58% 38 821
14/24/14 26 +0.19% 57,296
13/24/13 25.95 0.00% 73,931
10/24/10 25.95 0.00% 29,343
09/24/09 25.95 0.00% 46,316

End-of-day quote Taipei Exchange, May 15, 2024

More quotes
Chi Sheng Pharma & Biotech Co., Ltd, formerly Chi Sheng Chemical Corporation is principally engaged in the manufacture and distribution of general medicines and medicinal injections. The Company provides injections, including hemodialysis concentrate, amino acid injection with electrolytes, vitamins, cephalosporin antibiotics, antihistamines and antipruritics, as well as ginkgo injections; oral preparations, including antibiotics, cold syrups and liquid antacid; external medicines, including contact lens fluid, normal saline for wash and povidone-iodine solution, and consumer goods, including functional health foods, skin care products and cosmetics. It also provides medical devices and equipment. The Company distributes its products in domestic markets and to overseas markets, including Mainland China and Southeast Asia.
More about the company

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW